Tanvex BioPharma USA, Inc. | WebDisclosure

Basculer en Français

10965	Companies
240124	Keywords
168896	Articles
129224	Press releases

Headlines Articles Press releases Tanvex BioPharma USA, Inc.

Home
Companies
Tanvex BioPharma USA, Inc.

BRIEF

published on 08/19/2024 at 13:05, 2 years ago

Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05

FDA Approval Cancer Treatment Healthcare Innovation Biosimilar Neutropenia
BRIEF

published on 08/19/2024 at 13:05, 2 years ago

Tanvex BioPharma USA, Inc. franchit deux étapes réglementaires aux États-Unis : la FDA approuve Nypozi(TM) et la FDA accepte la demande de licence de produits biologiques biosimilaires pour le TX-05

Traitement Du Cancer Approbation De La FDA Biosimilaire Innovation Dans Le Domaine De La Santé Neutropénie
PRESS RELEASE

published on 08/19/2024 at 13:00, 2 years ago

Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05
Tanvex BioPharma USA, Inc. receives FDA approval for NYPOZI™ biosimilar and FDA BLA acceptance for TX-05, showcasing expertise in biologics development and manufacturing

FDA Approval Biologics Tanvex BioPharma NYPOZI TX-05
PRESS RELEASE

published on 10/16/2023 at 14:00, 2 years 10 months ago

Tanvex CDMO Launch Empowers Advancements in Novel Biologics and Biosimilars

Accesswire

Published on 09/11/2026 at 21:25, 44 minutes ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 5 hours 9 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 5 hours 9 minutes ago

Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 6 hours 44 minutes ago

Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 7 hours 9 minutes ago

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 19:44, 2 hours 25 minutes ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 3 hours 54 minutes ago

CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:07, 4 hours 2 minutes ago

Holding(s) in Company
Published on 09/11/2026 at 18:06, 4 hours 3 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 09/11/2026 at 18:00, 4 hours 9 minutes ago

ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL

Les Echos

Published on 09/11/2026 at 07:00, 15 hours 9 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 15 hours 9 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 15 hours 9 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 15 hours 9 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 2 hours ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE